Tip os
Log ind
Hans Schambye - red.jpg
Foto: Hans Schambye

BMS’ takeover decision looms after ”overwhelming” data from Galecto

Top picks in English:

Galecto Biotech has presented “ground-breaking” data from a phase II study with a candidate it partnered with Bristol-Myers Squibb on back in 2014. The clock is now ticking for BMS, which has to decide whether or not to use an option to buy the Denmark-based biotech.


BY STEFAN SINGH KAILAY
Offentliggjort 13.03.17 kl. 15:50

Log ind for at læse artikler

Velkommen til MedWatch. En del af vores indhold er eksklusivt og forbeholdt vores brugere.

Prøv os gratis i 14 dage

Få fuld adgang til vores kvalitetsjournalistik med et gratis prøveabonnement.

Sign up for MedWatch newsletter
Mest læste Top picks in English

Here is what Danish drug companies pay their workers

Løn Top picks in English:

The average monthly salary in the private pharmaceutical industry in Denmark is DKK 57,109. Make the jump to find out which company pays the highest wages and learn how much the rest of the industry pays as well.

Viagra copies cost less than 3 kroner

Top picks in English:

Since Viagra lost patent on June 24, 2013, generic versions of the drug have made the price drop by a staggering 97 %, according to a new analysis from a Danish pharmacy association. It could save Danish consumers millions per year.

Novo chief: ”This is data the world has never seen before”

Top picks in English:

Strong phase II data from Novo Nordisk’s pipeline-hope semaglutide gives cause for optimism for chief science officer Mads Krogsgaard Thomsen, who believes Novo holds a new generation of obesity medicine.

Novo Nordisk shows ”extremely strong data” in obesity trial

Top picks in English:

Novo Nordisk leads the way when it comes to medical treatment of obesity. According to Sydbank analyst Søren Løntoft Hansen, the brand new results from a phase II clinical trial with pipeline jewel semaglutide more than meet FDA’s requirements for obesity drugs.

Saniona spins out cancer project in new firm

Top picks in English:

Scandion Oncology, a spinoff from Saniona, has high hopes for the company’s candidate drug for the treatment of cancer. The drug has already been through clinical phase I and the plan is to begin phase II clinical trials on cancer patients within two years.

Price drop triggers Danish Viagra boom

Top picks in English:

Viagra is more popular than ever in Denmark, after the price of a single pill has dropped to less than 3 kroner following patent loss. New numbers show that sales have gone up by 60 % in a month.

Forsiden lige nu

Nye veje til kunderne skal skabe vækst i rehabselskab

Buus.jpg Medico & Rehab:

Det har været et stærkt år for rehabselskabet Vela, og nu skal selskabets netop lancerede treårsplan åbne for nye indgangsvinkler til kunderne og et yderligere løft i omsætningen.

AstraZeneca-boss var bedst betalte medicinalchef i 2016

Medicinal & Biotek:

Pascal Soriot fra Astrazeneca var i 2016 den europæiske medicinalchef, der kunne sætte det største beløb ind på kontoen, viser opgørelse.

MedWatch-indeks: Lundbeck til tops i nyhedsfattig uge

Medicinal & Biotek:

Både Novo Nordisk og Genmab høstede positiv omtale i ugens løb, men alligevel er det Lundbeck, der løber med denne uges topplacering i MedWatch-indekset.

Dansk medicoselskab går konkurs

Medico & Rehab:

Direktøren for LJ Medical Nordic havde satset på, at han kunne vende skuden i selskabet efter flere års svingende resultater, men de planer er ikke lykkes, og selskabet er nu meldt konkurs.

Sanofi indgår milliardaftale med Novo-partner

Medicinal & Biotek:

Den franske medicinalkoncern Sanofi har skrevet under på en aftale med et belgisk biotekselskab, som også arbejder sammen med Novo Nordisk. Aftalen har en potentiel værdi af flere milliarder.

Coloplast-konkurent køber ind i USA

Medico & Rehab:

En af Coloplasts konkurrenter, som Novo A/S for nyligt investerede i, har været ude og købe ind på det amerikanske marked for et trecifret millionbeløb.

ANNONCE
ANNONCE


ANNONCE